Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC
Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.
Perioperative Toripalimab Plus Chemotherapy Patients With Resectable Stage Iii Non Small Cell Lung Cancer Neotorch Study Shun Lu Shanghai Jiaotong University
Source: onclive.com